Allurion Technologies (ALUR) Stock

$5.15 -0.08 (-1.53%)
Market Cap: $24.68M | NYSE

Allurion Technologies Chart


Company Profile

Price: $5.15

Market Cap: $24.68M

Exchange: NYSE

CEO: Dr. Shantanu K. Gaur M.D.

Sector: Healthcare

Industry: Medical - Devices

Employees: 501

Headquarters: Natick, MA

Business Summary

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.

Allurion Technologies News

Allurion Relaunches in France

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it is relaunching the Allurion Balloon in France after ANSM, the French regulatory authority, cleared Allurion to resume sales. “We are thrilled the Allurion Balloon will once again serve French patients as a clinically proven treatment for obesity,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “Historically, France has been.

News image

How Much Upside is Left in Allurion Technologies, Inc. (ALUR)? Wall Street Analysts Think 374.67%

The mean of analysts' price targets for Allurion Technologies, Inc. (ALUR) points to a 374.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

News image

Allurion Technologies Shares Are Up Today: What's Going On?

Allurion Technologies ALUR shares are moving higher Friday, potentially in response to the company's Thursday announcement of a planned clinical study to evaluate the combination of its Allurion Program with GLP-1 agonists.

News image

Allurion Stock Triples on Plan to Test Gastric Balloon With Obesity Drugs

Shares of Allurion Technologies (ALUR) tripled Friday as the maker of the Allurion Gastric Balloon weight-loss device looked to take advantage of the booming obesity drug market.

News image

Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,240,000 shares of the Company's common stock at a price of $6.00 per share in a registered direct offering priced at-the-market under NYSE rules. In addition, in a concurrent private placement, the Compan.

News image

Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition. Previous studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost.1 In contrast, in previous.

News image

Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) dated January 15, 2025 for U.S. Patent No. 12,209,677 titled “Binary Fluid Control Valve System”. This patent covers additional claims for an enhanced, next-generation version of Allurion's proprietary Balloon technology and the introduction of in.

News image

Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a subscription agreement with funds affiliated with RTW Investments, LP (“RTW”) for the purchase and sale of 841,751 shares of the Company's common stock in a private placement at a purchase price of $2.97 per share. The private placement is expected to result in gross proceeds of $2.5 million and extend the Compa.

News image

Allurion Technologies, Inc. Announces Reverse Stock Split

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that its Board of Directors has determined to effect a one-for-twenty five reverse stock split of the Company's common stock, par value $0.0001 per share (the “Common Stock”). The reverse stock split will take effect at 12:01 a.m. Eastern Time on January 3, 2025, and the Company's Common Stock will begin trading on a split-adjusted basis.

News image

Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it received an Acceptance Letter from the Listings Operations Committee of the New York Stock Exchange (the “NYSE”) stating that the NYSE has accepted the Company's previously submitted plan to regain compliance with the NYSE's continued listing standard set forth in Section 802.01B of the NYSE's Listed Company Manual (the “Minimum Market Capitalization Standard”.

News image

Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the launch of AllurionMeds, a unique offering to patients that combines affordable and accessible weight loss medications with the company's AI-native platform, featuring Coach Iris, to promote long-term weight maintenance, virtual access to dieticians and a connected smart scale measuring not just weight but muscle and bone mass. “Feedback from patients is clear; the.

News image

Allurion Technologies Inc. (ALUR) Q3 2024 Earnings Call Transcript

Allurion Technologies Inc. (NYSE:ALUR ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Mike Cavanaugh – Investor Relations Shantanu Gaur – Founder and Chief Executive Officer Brian Conyer – Vice President-Digital Health Adrian Wild – Senior Vice President-International Commercial Chris Geberth – Chief Financial Officer Conference Call Participants Josh Jennings – TD Cowen Matt Taylor – Jefferies Operator Thank you for standing by. My name is John, and I'll be your conference operator today.

News image

Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (int.

News image

ALUR Stock Declines Despite Submitting PMA for Allurion Balloon

Allurion submits the first three modules of PMA application to the FDA for the Allurion Balloon.

News image

October's 4 Best Penny Stocks: High-Risk, High-Reward Picks

Most investors' definition of a penny stock has broadened to include not just companies trading at less than $1 per share, but also those with slightly higher stock prices up to about $5 per share. Regardless of your exact threshold, these firms remain a high-risk, high-reward proposition.

News image

Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a systematic review and meta-analysis evaluating the effectiveness and safety of the Allurion Program. The analysis reviewed studies conducted between 2016 and 2024 and included data from 11 observational studies comprising a total of 2,107 patients. The results of the meta-analysis demonstrated a mean weight reduction of 12.5% and significant reduc.

News image

Allurion Technologies Inc. (ALUR) Q2 2024 Earnings Call Transcript

Allurion Technologies Inc. (NYSE:ALUR ) Q2 2024 Earnings Call Transcript August 13, 2024 8:30 AM ET Company Participants Mike Cavanaugh - IR Shantanu Gaur - Founder and CEO Chris Geberth - CFO Conference Call Participants Keay Nakae - Chardan Matt Taylor - Jefferies Operator Thank you for standing by. My name is Bailey and I will be your conference operator today.

News image

Allurion to Report Second Quarter 2024 Financial Results on August 13, 2024

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for the second quarter 2024 on Tuesday, August 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (intern.

News image

Allurion Announces Launch of Offering of Common Stock and Warrants

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it has launched an underwritten public offering of up to $20 million of its common stock, par value $0.0001 per share (the “Shares”), and warrants to purchase Shares (the “Warrants” and, together with the Shares, the “Securities”). Jefferies and TD Cowen are acting as joint book-running managers and representatives of the underwriter.

News image

Why Is Allurion (ALUR) Stock Up 140% Today?

Among the medical companies seeing a big uptick today, Allurion (NYSE: ALUR ) could be among the most closely watched on Thursday. At the time of this writing, ALUR stock is up more than 140% as investors price in some very positive news from the small-cap weight loss-focused name.

News image

Allurion Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight Loss

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average lean mass gain of 5.6% in patients with an average weight loss of 14% at four months on the Allurion Program. Vital signs and physical activity were tracked in real-time with the Allurion App, Connected Scale, and Health Tracker, and follow-up was provided through the AI-powered Allurion Virtual Care Suite. In the st.

News image

Allurion (ALUR) Unveils Positive Data for Its Balloon Therapy

Allurion (ALUR) announces positive weight loss data for its gastric balloon technology.

News image

Allurion Technologies, Inc. (ALUR) Loses -38.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Allurion Technologies, Inc. (ALUR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

News image

Allurion Announces Three Scientific Presentations at the 40th Annual Meeting of the American Society for Metabolic and Bariatric Surgery

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three scientific presentations at the American Society for Metabolic and Bariatric Surgery Annual Meeting (ASMBS) taking place in San Diego, California, June 9-13, 2024. Data from a study of 121 patients across 11 obesity centers treated with two consecutive, four-month Allurion Balloons showed patients achieved 22.1% weight loss on average at one year. In comparison,.

News image

Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company's Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working.

News image

Allurion Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the expansion of its Artificial Intelligence (AI)-powered weight loss coach, Coach Iris, to support patients prescribed GLP-1s and other anti-obesity medications and the first commercial agreements for its Virtual Care Suite (VCS) in the United States. With this update to Coach Iris, patients now have access to 24/7 personalized coaching and guidance specific to GLP-1.

News image

Allurion to Participate in Two Upcoming Investor Conferences in June 2024

NATICK, Mass.--(BUSINESS WIRE)--Allurion to Participate in Two Upcoming Investor Conferences in June 2024.

News image

Allurion Announces Three Scientific Presentations at the European Congress on Obesity, Including Study on Lean Mass Preservation for Sustainable, Healthy Weight Loss

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three scientific presentations at the 31st European Congress on Obesity (ECO) held in Venice, Italy, on 12-15 May, 2024. Presentations include data from a study of 712 patients treated with the Allurion Program, which is anchored by the Allurion Balloon and enhanced by the Virtual Care Suite featuring Allurion's proprietary behavior change program. This study was cond.

News image

Allurion Reports First Quarter 2024 Financial Results and Provides Business Update

NATICK, Mass.--(BUSINESS WIRE)--Allurion Reports First Quarter 2024 Financial Results and Provides Business Update.

News image

Allurion Technologies Earnings

This section highlights Allurion Technologies's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.

Next Earnings Date

Date: March 20, 2025
Time: Before Market
Est. EPS: $-4.75
Status: Unconfirmed

Last Earnings Results

Date: November 13, 2024
EPS: $-3.50
Est. EPS: $-4.25
Revenue: $5.37M

Earnings Call Transcripts

Transcript Quarter Year Date Estimated EPS Actual EPS
Read Transcript Q3 2024 2024-11-13 $-4.25 $-3.50
Read Transcript Q2 2024 2024-08-13 $-0.24 $0.25
Read Transcript Q1 2024 2024-05-14 $-0.30 $2.75
Read Transcript Q4 2023 2024-03-21 $-12.75 $-15.75
Read Transcript Q3 2023 2023-11-17 N/A N/A

Financial Statements

Access annual & quarterly financial statements for Allurion Technologies, including income statements, balance sheets, and cash flow statements..

Annual Income Statement

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Revenue $53.47M $64.21M $38.24M $-
Cost of Revenue $11.97M $13.48M $9.05M $-
Gross Profit $41.50M $50.73M $29.19M $-
Gross Profit Ratio 77.61% 79.00% 76.33% 0.00%
Research and Development Expenses $27.69M $16.97M $5.73M $-
General and Administrative Expenses $46.02M $15.37M $8.82M $-
Selling and Marketing Expenses $46.86M $50.41M $27.14M $-
Selling General and Administrative Expenses $92.88M $65.77M $35.96M $4.56K
Other Expenses $- $-1.15M $-555.00K $-610
Operating Expenses $120.58M $82.74M $41.69M $5.17K
Cost and Expenses $132.54M $96.22M $50.74M $5.17K
Interest Income $- $10.66M $49.77K $-
Interest Expense $10.57M $4.43M $3.67M $-
Depreciation and Amortization $746.00K $895.00K $707.00K $206.30K
EBITDA $-69.03M $-32.28M $-12.35M $-5.17K
EBITDA Ratio -129.11% -48.52% -32.29% 0.00%
Operating Income $-79.08M $-32.01M $-12.50M $-5.17K
Operating Income Ratio -147.90% -49.85% -32.69% 0.00%
Total Other Income Expenses Net $-1.26M $-5.59M $115.00K $1
Income Before Tax $-80.34M $-37.60M $-12.39M $-5.17K
Income Before Tax Ratio -150.27% -58.56% -32.39% 0.00%
Income Tax Expense $264.00K $143.00K $3.11M $-206.30K
Net Income $-82.30M $-37.74M $-12.39M $-5.17K
Net Income Ratio -153.93% -58.78% -32.39% 0.00%
EPS $-2.31 $-1.40 $-0.11 $0.00
EPS Diluted $-2.31 $-1.40 $-0.11 $0.00
Weighted Average Shares Outstanding 35.58M 26.92M 107.81M 107.81M
Weighted Average Shares Outstanding Diluted 35.58M 26.92M 107.81M 107.81M
SEC Filing Source Source Source Source


Income Statement Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021
Revenue $5.37M $11.77M $9.39M $8.23M $18.20M $12.96M $14.07M $19.18M $16.06M $16.25M $12.71M $- $- $- $-
Cost of Revenue $2.26M $2.77M $2.69M $1.91M $4.23M $2.99M $2.94M $3.94M $3.47M $3.50M $2.58M $- $- $- $-
Gross Profit $3.11M $8.99M $6.70M $6.33M $13.97M $9.97M $11.13M $15.24M $12.59M $12.76M $10.14M $- $- $- $-
Gross Profit Ratio 57.97% 76.43% 71.38% 76.85% 76.75% 76.91% 79.11% 79.46% 78.37% 78.49% 79.74% 0.00% 0.00% 0.00% 0.00%
Research and Development Expenses $3.21M $4.26M $5.68M $6.02M $7.19M $6.58M $7.85M $5.73M $5.07M $3.10M $3.07M $- $- $- $-
General and Administrative Expenses $7.04M $7.31M $6.39M $15.37M $18.94M $6.41M $5.31M $4.72M $3.82M $3.05M $3.78M $- $- $- $-
Selling and Marketing Expenses $5.20M $6.72M $6.14M $10.73M $13.99M $10.27M $11.86M $14.94M $15.69M $10.90M $8.87M $- $- $- $-
Selling General and Administrative Expenses $12.24M $14.03M $12.31M $26.04M $32.93M $16.68M $17.17M $19.66M $19.51M $13.95M $12.65M $603.98K $419.77K $663.77K $343.74K
Other Expenses $- $- $172.00K $-776.00K $389.00K $-85.00K $-135.00K $-272.00K $-420.00K $-287.00K $-167.00K $-52.60K $-49.86K $-49.32K $-48.27K
Operating Expenses $15.45M $18.15M $17.99M $32.07M $40.12M $23.26M $25.02M $25.39M $24.57M $17.05M $15.72M $656.58K $469.63K $713.10K $392.00K
Cost and Expenses $17.71M $21.11M $20.68M $33.97M $44.35M $26.25M $27.96M $29.33M $28.05M $20.54M $18.30M $656.58K $469.63K $713.09K $392.01K
Interest Income $- $- $- $- $- $- $1.01M $5.47M $3.90M $- $- $16.36K $13.25K $13.11K $7.06K
Interest Expense $- $339.00K $1.93M $3.23M $2.59M $2.51M $2.24M $1.76M $1.14M $825.00K $702.00K $- $- $- $-
Depreciation and Amortization $214.00K $197.00K $367.00K $188.00K $160.00K $154.00K $245.00K $1.35M $229.00K $210.00K $213.00K $- $- $- $-
EBITDA $-12.34M $-1.56M $7.96M $-15.58M $-18.85M $-19.31M $-15.29M $-9.19M $-12.11M $-4.37M $-5.50M $2.45M $19.18M $-10.69M $-5.18M
EBITDA Ratio -229.94% -13.27% -116.38% -310.26% -141.57% -102.04% -97.94% -47.29% -75.80% -26.89% -43.56% 0.00% 0.00% 0.00% 0.00%
Operating Income $-12.34M $-9.25M $-11.29M $-25.74M $-26.15M $-13.29M $-13.89M $-10.15M $-11.98M $-4.29M $-5.58M $-656.58K $-469.63K $-713.10K $-392.00K
Operating Income Ratio -229.94% -78.58% -120.29% -312.54% -143.70% -102.58% -98.72% -52.90% -74.61% -26.42% -43.92% 0.00% 0.00% 0.00% 0.00%
Total Other Income Expenses Net $3.41M $7.15M $-5.73M $6.73M $4.56M $-8.68M $-3.88M $-2.15M $-1.49M $-1.11M $-835.00K $3.10M $19.65M $-9.97M $-4.79M
Income Before Tax $-8.94M $-2.10M $5.66M $-19.01M $-21.60M $-21.97M $-17.77M $-12.30M $-13.48M $-5.41M $-6.42M $2.45M $19.18M $-10.69M $-5.18M
Income Before Tax Ratio -166.48% -17.82% 60.32% -230.80% -118.66% -169.55% -126.27% -64.12% -83.90% -33.26% -50.49% 0.00% 0.00% 0.00% 0.00%
Income Tax Expense $69.00K $65.00K $76.00K $174.00K $34.00K $22.00K $34.00K $48.00K $95.00K $538.00K $535.00K $- $- $- $-
Net Income $-9.00M $-2.16M $5.59M $-19.18M $-21.63M $-22.00M $-17.80M $-12.35M $-13.57M $-5.41M $-6.42M $2.45M $19.18M $-10.69M $-5.18M
Net Income Ratio -167.77% -18.37% 59.51% -232.91% -118.85% -169.72% -126.51% -64.37% -84.49% -33.26% -50.49% 0.00% 0.00% 0.00% 0.00%
EPS $-0.14 $-0.05 $0.12 $-0.40 $-0.54 $-2.86 $-0.58 $-0.11 $-0.29 $-0.12 $-0.14 $0.02 $0.18 $-0.10 $-0.05
EPS Diluted $-0.14 $-0.05 $0.11 $-0.40 $-0.54 $-2.86 $-0.58 $-0.11 $-0.29 $-0.12 $-0.14 $0.02 $0.18 $-0.10 $-0.05
Weighted Average Shares Outstanding 64.09M 47.95M 47.78M 47.52M 40.34M 7.68M 30.79M 107.81M 46.50M 46.50M 46.50M 107.81M 107.81M 107.81M 107.81M
Weighted Average Shares Outstanding Diluted 64.09M 47.95M 49.19M 47.52M 40.34M 7.68M 30.79M 107.81M 46.50M 46.50M 46.50M 107.81M 107.81M 107.81M 107.81M
SEC Filing Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source

Annual Balance Sheet

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Cash and Cash Equivalents $38.04M $7.68M $25.84M $47.09K
Short Term Investments $- $- $- $-
Cash and Short Term Investments $38.04M $7.68M $25.84M $47.09K
Net Receivables $18.19M $29.35M $6.83M $-
Inventory $6.17M $3.87M $2.71M $-
Other Current Assets $2.41M $2.49M $1.94M $-
Total Current Assets $64.82M $43.38M $37.33M $47.09K
Property Plant Equipment Net $6.39M $5.28M $1.71M $-
Goodwill $- $- $- $-
Intangible Assets $- $- $- $-
Goodwill and Intangible Assets $- $- $- $-
Long Term Investments $384.00K $94.33M $862.55M $-
Tax Assets $- $- $- $-
Other Non-Current Assets $121.00K $-91.62M $-862.24M $282.88K
Total Non-Current Assets $6.90M $7.99M $2.02M $282.88K
Other Assets $- $- $- $-
Total Assets $71.71M $51.37M $39.35M $329.96K
Account Payables $10.38M $5.81M $1.62M $-
Short Term Debt $39.55M $54.27M $24.14M $170.00K
Tax Payables $- $- $- $-
Deferred Revenue $- $- $202.00K $-
Other Current Liabilities $15.49M $15.79M $5.65M $140.13K
Total Current Liabilities $65.42M $75.87M $31.61M $310.13K
Long Term Debt $2.31M $5.27M $2.00M $-
Deferred Revenue Non-Current $- $- $- $-
Deferred Tax Liabilities Non-Current $- $- $- $-
Other Non-Current Liabilities $74.47M $41.67M $40.02M $-
Total Non-Current Liabilities $76.77M $46.94M $42.02M $-
Other Liabilities $- $- $- $-
Total Liabilities $142.20M $122.81M $73.64M $310.13K
Preferred Stock $- $58.00M $57.97M $-
Common Stock $5.00K $51.00K $51.00K $2.16K
Retained Earnings $-212.80M $-132.19M $-94.45M $-5.17K
Accumulated Other Comprehensive Income Loss $-700.00K $- $- $-
Other Total Stockholders Equity $143.01M $99.88M $2.14M $22.84K
Total Stockholders Equity $-70.49M $-71.44M $-34.28M $19.83K
Total Equity $-70.49M $-71.44M $-34.28M $19.83K
Total Liabilities and Stockholders Equity $71.71M $51.37M $39.35M $329.96K
Minority Interest $- $- $- $-
Total Liabilities and Total Equity $71.71M $51.37M $39.35M $329.96K
Total Investments $384.00K $94.33M $862.55M $-
Total Debt $41.86M $59.53M $26.14M $170.00K
Net Debt $3.82M $51.85M $300.00K $122.91K


Balance Sheet Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021
Cash and Cash Equivalents $28.65M $19.26M $29.68M $38.04M $79.87M $4.74M $9.94M $7.68M $1.01M $66.79K $272.50K $836.87K $958.65K $1.07M $68.28K
Short Term Investments $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Cash and Short Term Investments $28.65M $19.26M $29.68M $38.04M $79.87M $4.74M $9.94M $7.68M $1.01M $66.79K $272.50K $836.87K $958.65K $1.07M $68.28K
Net Receivables $9.94M $13.36M $16.16M $18.19M $27.64M $25.56M $28.99M $29.35M $- $- $- $- $- $- $-
Inventory $4.57M $4.79M $5.63M $6.17M $4.02M $4.86M $4.31M $3.87M $- $- $- $- $- $- $-
Other Current Assets $1.67M $2.90M $2.17M $2.41M $2.29M $1.91M $2.48M $2.49M $270.88K $470.61K $670.33K $774.68K $948.97K $1.13M $1.32M
Total Current Assets $44.83M $40.30M $53.64M $64.82M $113.82M $37.07M $45.73M $43.38M $1.28M $537.40K $942.83K $1.61M $1.91M $2.20M $1.39M
Property Plant Equipment Net $5.36M $5.74M $5.84M $6.39M $6.52M $5.91M $6.15M $5.28M $- $- $- $- $- $- $-
Goodwill $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Intangible Assets $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Goodwill and Intangible Assets $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Long Term Investments $- $388.00K $386.00K $384.00K $232.00K $368.00K $96.54M $94.33M $867.07M $863.85M $862.62M $862.55M $862.53M $862.52M $862.51M
Tax Assets $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Other Non-Current Assets $507.00K $122.00K $124.00K $121.00K $122.00K $8.80M $-90.45M $-91.62M $- $-1 $- $- $- $-1 $-
Total Non-Current Assets $5.87M $6.24M $6.35M $6.90M $6.87M $15.09M $12.24M $7.99M $867.07M $863.85M $862.62M $862.55M $862.53M $862.52M $862.51M
Other Assets $- $1 $1 $- $- $- $- $- $- $1 $- $- $- $1 $-
Total Assets $50.70M $46.55M $59.99M $71.71M $120.69M $52.15M $57.97M $51.37M $868.36M $864.38M $863.56M $864.16M $864.44M $864.72M $863.89M
Account Payables $10.39M $7.98M $11.94M $10.38M $9.36M $14.77M $13.71M $5.81M $- $- $- $- $- $- $-
Short Term Debt $878.00K $1.70M $40.59M $40.46M $59.42M $55.35M $54.39M $54.27M $913.52K $- $- $- $- $- $-
Tax Payables $- $- $- $- $- $- $27.15K $- $674.92K $219.37K $- $- $- $- $-
Deferred Revenue $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Other Current Liabilities $7.97M $13.87M $13.69M $14.59M $18.44M $19.77M $15.86M $15.79M $59.37K $32.89K $78.43K $371.01K $968.10K $791.37K $763.28K
Total Current Liabilities $19.24M $23.56M $66.22M $65.42M $87.23M $89.89M $83.98M $75.87M $1.65M $252.26K $78.43K $371.01K $968.10K $791.37K $763.28K
Long Term Debt $37.67M $42.74M $2.01M $2.31M $2.51M $22.61M $19.61M $5.27M $- $1.39M $1.35M $1.39M $1.38M $1.68M $-
Deferred Revenue Non-Current $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Deferred Tax Liabilities Non-Current $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Other Non-Current Liabilities $58.58M $50.84M $57.92M $74.47M $83.70M $50.00M $43.16M $41.67M $34.73M $39.23M $48.37M $61.41M $63.55M $82.90M $73.09M
Total Non-Current Liabilities $96.25M $93.57M $59.93M $76.77M $86.22M $72.61M $62.76M $46.94M $34.73M $40.62M $49.72M $62.81M $64.94M $84.58M $73.09M
Other Liabilities $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Liabilities $115.49M $117.13M $126.15M $142.20M $173.44M $162.49M $146.74M $122.81M $36.38M $40.87M $49.80M $63.18M $65.90M $85.37M $73.86M
Preferred Stock $- $- $- $- $- $58.03M $58.03M $58.00M $- $- $- $- $- $- $-
Common Stock $7.00K $5.00K $5.00K $5.00K $5.00K $51.00K $51.00K $51.00K $866.27M $863.23M $862.50M $862.50M $862.50M $774.35M $785.04M
Retained Earnings $-218.38M $-209.38M $-207.21M $-212.80M $-193.62M $-171.99M $-149.99M $-132.19M $-34.29M $-39.71M $-48.74M $-61.52M $-63.97M $-15.87M $-5.19M
Accumulated Other Comprehensive Income Loss $2.89M $-5.98M $-2.90M $-700.00K $- $- $- $- $- $- $- $- $- $- $-
Other Total Stockholders Equity $151.67M $144.77M $143.95M $143.01M $140.86M $3.56M $3.13M $218.32M $- $- $- $- $- $20.87M $10.19M
Total Stockholders Equity $-63.81M $-70.58M $-66.16M $-70.49M $-52.76M $-110.34M $-88.78M $-71.44M $831.98M $823.51M $813.76M $800.98M $798.54M $779.35M $790.04M
Total Equity $-63.81M $-70.58M $-66.16M $-70.49M $-52.76M $-110.34M $-88.78M $-71.44M $831.98M $823.51M $813.76M $800.98M $798.54M $779.35M $790.04M
Total Liabilities and Stockholders Equity $50.70M $46.55M $59.99M $71.71M $120.69M $52.15M $57.97M $51.37M $868.36M $864.38M $863.56M $864.16M $864.44M $864.72M $863.89M
Minority Interest $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Liabilities and Total Equity $50.70M $46.55M $59.99M $71.71M $120.69M $52.15M $57.97M $51.37M $868.36M $864.38M $863.56M $864.16M $864.44M $864.72M $863.89M
Total Investments $- $388.00K $386.00K $384.00K $232.00K $368.00K $96.54M $94.33M $867.07M $863.85M $862.62M $862.55M $862.53M $862.52M $862.51M
Total Debt $38.55M $43.59M $41.78M $41.86M $61.06M $77.12M $73.99M $59.53M $913.52K $1.39M $1.35M $1.39M $1.38M $1.68M $-
Net Debt $9.89M $24.33M $12.10M $3.82M $-18.80M $72.38M $64.05M $51.85M $-99.88K $1.32M $1.08M $556.08K $426.32K $608.13K $-68.28K

Annual Cash Flow

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Net Income $-80.61M $-37.74M $-12.39M $-5.17K
Depreciation and Amortization $746.00K $2.00M $707.00K $-
Deferred Income Tax $- $1.27M $665.00K $-
Stock Based Compensation $8.36M $437.00K $313.00K $-
Change in Working Capital $194.00K $-13.79M $-1.27M $5.13K
Accounts Receivables $-1.32M $-22.82M $-707.00K $-
Inventory $-3.71M $-1.15M $-1.28M $-
Accounts Payables $4.66M $3.32M $-488.00K $-
Other Working Capital $553.00K $6.86M $1.21M $5.13K
Other Non Cash Items $7.33M $840.00K $-2.35M $-0
Net Cash Provided by Operating Activities $-63.98M $-46.98M $-14.33M $-35
Investments in Property Plant and Equipment $-1.61M $-1.55M $-912.00K $-
Acquisitions Net $- $- $- $-
Purchases of Investments $- $- $-862.50M $-
Sales Maturities of Investments $- $- $- $-
Other Investing Activities $- $- $862.50M $-
Net Cash Used for Investing Activities $-1.61M $-1.55M $-912.00K $-
Debt Repayment $71.00K $30.95M $19.07M $170.00K
Common Stock Issued $213.00K $132.00K $864.13M $25.00K
Common Stock Repurchased $- $- $- $-
Dividends Paid $- $- $- $-
Other Financing Activities $95.92M $-548.00K $9.87M $-147.88K
Net Cash Used Provided by Financing Activities $95.99M $30.54M $28.95M $47.12K
Effect of Forex Changes on Cash $- $- $- $-
Net Change in Cash $30.40M $-17.99M $13.70M $47.09K
Cash at End of Period $38.42M $8.02M $26.02M $47.09K
Cash at Beginning of Period $8.02M $26.02M $12.31M $-
Operating Cash Flow $-63.98M $-46.98M $-14.33M $-35
Capital Expenditure $-1.61M $-1.55M $-912.00K $-
Free Cash Flow $-65.59M $-48.53M $-15.24M $-35

Cash Flow Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 June 30, 2021 March 31, 2021
Net Income $-9.00M $-2.16M $5.59M $-19.18M $-21.63M $-22.00M $-17.80M $-12.35M $-13.57M $-5.41M $-6.42M $2.45M $-10.69M $-5.18M
Depreciation and Amortization $214.00K $197.00K $367.00K $188.00K $159.00K $154.00K $245.00K $1.35M $229.00K $210.00K $213.00K $- $- $-
Deferred Income Tax $- $- $- $-1.45M $13.91M $9.33M $2.42M $973.00K $85.00K $251.00K $-34.00K $- $- $-
Stock Based Compensation $1.67M $- $552.00K $2.01M $5.54M $401.00K $409.00K $182.00K $93.00K $89.00K $73.00K $- $- $-
Change in Working Capital $-1.97M $-1.05M $2.57M $-3.19M $-4.51M $4.00M $3.89M $-5.64M $2.66M $-7.50M $-3.31M $534.80K $468.87K $-1.20M
Accounts Receivables $2.79M $2.74M $1.67M $2.56M $-4.81M $1.36M $-427.00K $-8.99M $-1.68M $-7.79M $-4.35M $- $- $-
Inventory $-463.00K $684.00K $330.00K $-2.81M $569.00K $-1.02M $-449.00K $446.00K $-807.00K $-357.00K $-432.00K $- $- $-
Accounts Payables $1.93M $-4.05M $1.55M $1.17M $-1.53M $-333.00K $5.35M $269.00K $932.00K $160.00K $1.96M $- $- $-
Other Working Capital $-6.22M $-423.00K $-983.00K $-4.12M $1.27M $4.00M $-590.00K $2.64M $4.22M $487.00K $-487.00K $534.80K $468.87K $-1.20M
Other Non Cash Items $-2.37M $-5.91M $-19.98M $753.00K $-16.57M $-1.59M $526.00K $-236.00K $377.00K $322.00K $377.00K $-3.10M $9.97M $4.79M
Net Cash Provided by Operating Activities $-11.46M $-8.93M $-8.64M $-20.87M $-23.09M $-9.70M $-10.32M $-15.73M $-10.13M $-12.03M $-9.10M $-121.78K $-244.22K $-1.60M
Investments in Property Plant and Equipment $-72.00K $-435.00K $-104.00K $-398.00K $-800.00K $-131.00K $-277.00K $-459.00K $157.00K $-930.00K $-318.00K $- $- $-
Acquisitions Net $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Purchases of Investments $- $- $- $- $- $1.20M $-1.20M $- $- $- $- $-862.50M $- $-
Sales Maturities of Investments $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Other Investing Activities $- $- $- $- $- $-1.20M $1.20M $776.14M $- $- $- $862.50M $- $-862.50M
Net Cash Used for Investing Activities $-72.00K $-435.00K $-104.00K $-398.00K $-800.00K $-131.00K $-277.00K $-459.00K $157.00K $-930.00K $-318.00K $- $- $-862.50M
Debt Repayment $- $280.00K $- $-20.00M $1.02M $5.45M $1.20M $14.93M $9.95M $4.97M $1.10M $- $1.50M $-264.10K
Common Stock Issued $20.93M $17.00K $378.00K $18.00K $134.00K $61.00K $- $- $- $- $- $- $-250.00K $864.38M
Common Stock Repurchased $- $- $- $- $- $- $- $-776.54M $- $- $- $- $- $-
Dividends Paid $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Other Financing Activities $20.93M $-1.36M $9.00K $-426.00K $97.87M $-809.00K $11.67M $-285.00K $-162.00K $-32.00K $63.00K $- $-1 $-
Net Cash Used Provided by Financing Activities $20.93M $-1.06M $387.00K $-20.41M $98.89M $4.64M $12.87M $14.64M $9.79M $4.94M $1.17M $- $1.25M $864.12M
Effect of Forex Changes on Cash $- $- $- $-152.00K $- $- $- $-1.00K $- $1.00K $- $- $- $-
Net Change in Cash $9.79M $-10.42M $-8.36M $-41.83M $74.99M $-5.19M $2.27M $-1.55M $-182.00K $-8.02M $-8.25M $-121.78K $1.01M $21.19K
Cash at End of Period $29.05M $19.65M $29.68M $38.04M $80.10M $5.11M $10.29M $8.02M $9.57M $9.75M $17.77M $836.87K $1.07M $68.28K
Cash at Beginning of Period $19.26M $30.07M $38.04M $79.87M $5.11M $10.29M $8.02M $9.57M $9.75M $17.77M $26.02M $958.65K $68.28K $47.09K
Operating Cash Flow $-11.46M $-8.93M $-8.64M $-20.87M $-23.09M $-9.70M $-10.32M $-15.73M $-10.13M $-12.03M $-9.10M $-121.78K $-244.22K $-1.60M
Capital Expenditure $-72.00K $-435.00K $-104.00K $-398.00K $-800.00K $-131.00K $-277.00K $-459.00K $157.00K $-930.00K $-318.00K $- $- $-
Free Cash Flow $-11.54M $-9.36M $-8.74M $-21.27M $-23.89M $-9.83M $-10.60M $-16.18M $-9.97M $-12.96M $-9.42M $-121.78K $-244.22K $-1.60M


Allurion Technologies Stock Forecast

Analyst ratings, price targets, and earnings estimates for ALUR.

ALUR Analyst Ratings

Strong Buy

Buy
2
Hold
0
Sell
0

Based on 2 analysts in the past 3 months

ALUR Stock 12 Month Forecast

$5.00

▼ (-2.91% Downside)
Highest Price Target
$ (0.0%)
Average Price Target
$5.00 (-2.9%)
Lowest Price Target
$ (0.0%)

Based on 1 analysts in the last year

Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
High $35.89M
Average $32.80M
Low $29.01M
3 analysts
Net Income Estimates
High $-164.39M
Average $-322.37M
Low $-480.35M
3 analysts
EPS Estimates
High $-4.62
Average $-7.36
Low $-13.50
3 analysts
Revenue Estimates
High $54.49M
Average $43.70M
Low $36.24M
3 analysts
Net Income Estimates
High $-159.85M
Average $-215.60M
Low $-271.36M
3 analysts
EPS Estimates
High $-4.49
Average $-5.77
Low $-7.63
1 analysts
Revenue Estimates
High $77.93M
Average $62.50M
Low $51.83M
1 analysts
Net Income Estimates
High $-132.07M
Average $-178.14M
Low $-224.20M
1 analysts
EPS Estimates
High $-3.71
Average $-4.77
Low $-6.30
1 analysts
Revenue Estimates
High $265.59M
Average $213.00M
Low $176.65M
1 analysts
Net Income Estimates
High $270.26M
Average $204.59M
Low $159.21M
1 analysts
EPS Estimates
High $7.60
Average $5.75
Low $4.47
1 analysts
Latest Price Target Updates
Date Analyst Firm Price Target Price When Posted Upside
Apr 04, 2024 Keay Nakae Chardan Capital $5.00 $1.73 189.0%

Allurion Technologies Dividends

Explore Allurion Technologies's dividend history, including dividend yield, payout ratio, and historical payments.

Allurion Technologies does not currently pay a dividend.

Peers: Medical - Devices

This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.

Company Market Cap Price EPS P/E Ratio P/B Ratio
Current Reports (8-K)
Ownership